| Date | Title | Description |
| 15.05.2024 | Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates | Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease expected in second half of 2024 Submitted Investigational New Drug application to U.S. Food and Drug Admini... |
| 08.03.2024 | Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference | - |
| 11.05.2023 | Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates | /EIN News/ -- Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose
Open label extension trial to be extended, providing up to 36 months of long-term exposure data
ATH-1105 significantly pro... |
| 29.09.2022 | Promising data from large Alzheimer’s study bodes well for this Seattle startup | AltPep CEO and founder Valerie Daggett. (AltPep Photo)
Alzheimer’s disease researchers were buoyed by positive data released Tuesday from a large clinical trial of an experimental therapy being developed by Biogen and Eisai.
The early data ... |
| 22.10.2021 | Athira Pharma : Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer's Disease | Topline data targeted for 1H22
BOTHELL, WA, OCTOBER 22, 2021 - Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira"), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and sto... |
| 21.10.2021 | Athira chief executive resigns as company confirms she altered research | The chief executive of biotech Athira Pharma has permanently left the company after papers she published as a graduate student were found to contain altered research. Leen Kawas was suspended in June, after STAT asked the Alzheimer’s resear... |
| 21.10.2021 | Athira Pharma : Announces Leadership Changes | Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer
Special Committee of the Board of Directors has concluded its investigation of Dr. Leen Kawas's Doctoral Research... |
| 21.10.2021 | Ex-Athira Pharma CEO Leen Kawas resigns and leaves board after image manipulation investigation | Leen Kawas. (Athira Pharma Photo)
Leen Kawas has formally resigned as CEO and president of Athira Pharma and is stepping off the board after an investigation found the biotech executive altered images in scientific papers she authored.
Mark... |
| 22.09.2020 | Seattle based Athira Pharma raises US$ 204M in IPO | - |
| 22.09.2020 | Athira Pharma Raises $204m in Initial Public Offering | - |
| 18.09.2020 | Athira Pharma raises $204M in IPO, reaching ‘big milestone’ in fight against Alzheimer’s and other diseases | Athira Pharma CEO Leen Kawas accepts the award for CEO of the Year at the 2019 GeekWire Awards. (GeekWire Photo / Kevin Lisota)
More than 5 million Americans have Alzheimer’s disease, and the number is projected to rise to nearly 14 million... |
| 17.09.2020 | Athira Pharma prices IPO at $17/share, will raise $204M in third Washington state IPO of 2020 | The Athira team. (Athira Photo)
Athira Pharma will raise at least $204 million as the Seattle biotech startup becomes a public company on Friday.
Athira priced its IPO on Thursday evening at $17 per share, which came in at the high end of i... |
| 03.09.2020 | This 35-year-old female CEO is about to crack the glass ceiling, shattering a dismal IPO track record | Clinical pharmacist and Athira Pharma CEO Leen Kawas speaking at the 2018 GeekWire Summit. (GeekWire Photo / Kevin Lisota)
Leen Kawas is truly a unicorn.
The 35-year-old co-founder and CEO of Seattle biotechnology company Athira Pharma woul... |
| 26.08.2020 | Seattle’s Athira Pharma files for IPO to fund quest for Alzheimer’s and Parkinson’s breakthroughs | The Athira team. (Athira Photo)
Athira Pharma is aiming to go public.
The Seattle biotech filed initial IPO paperwork Wednesday, a surprising move that would give the company additional capital to develop its therapies for brain diseases.
F... |
| 05.06.2020 | Athira Pharma raises $85 million in Series B round | Athira Pharma said Thursday that it had raised $85 million in a Series A funding round, led by Perceptive Advisors. New firms participating in the round included RTW Investments, Viking Global Investors, Venrock Healthcare Capital Partners,... |
| 05.06.2020 | Athira Pharma Closes $85 Million Series B Financing | - |
| 04.06.2020 | Athira reels in $85M for phase 2/3 Alzheimer's study | Athira Pharma changed its name last year to reflect its focus on regenerative medicine. Now, it’s snagged $85 million to advance those medicines, which includes bankrolling a phase 2/3 trial in Alzheimer’s for its lead asset.
Formerly known... |
| 04.06.2020 | Seattle biotech startup Athira raises $85M to develop therapies for Alzheimer’s and Parkinson’s | The Athira team. (Athira Photo)
The foundation of Athira Pharma began while Leen Kawas was earning her Ph.D. in molecular pharmacology at Washington State University nearly a decade ago.
Fast forward to today and the Seattle biotech startup... |
| 04.06.2020 | Athira Pharma Closes $85M Series B Financing | Athira Pharma, Inc., a Seattle, WA-based clinical-stage company developing innovative first-in-class regenerative therapies with the potential to restore brain function, closed an $85m Series B financing.
The round was led by Perceptive Adv... |
| 04.06.2020 | Athira reels in $85M for phase 2/3 Alzheimer's study | Athira Pharma changed its name last year to reflect its focus on regenerative medicine. Now, it’s snagged $85 million to advance those medicines, which includes bankrolling a phase 2/3 trial in Alzheimer’s for its lead asset.
Sponsored by A... |
| 04.06.2020 | Athira Pharma Announces $85M Series B |
SEATTLE, WA, Athira Pharma today announced the closing of an $85 million Series B financing.
>> Click here for more funding data on Athira Pharma
>> To export Athira Pharma funding data to PDF and Excel, click here
Athira... |
| 03.05.2019 | Revealed: GeekWire Awards 2019 winners crowned as we celebrate the best of Pacific Northwest tech | (GeekWire Photo / Taylor Soper)
The strength and success of the people and companies across the Pacific Northwest tech ecosystem was on full display Thursday night at the GeekWire Awards.
It was so much fun celebrating with more than 900 of... |
| 11.04.2019 | GeekWire Awards 2019: Here’s what makes these Startup CEO of the Year nominees great leaders | The Startup CEO of the Year finalists, from left to right, clockwise: Leen Kawas, Athira Pharma; Scott Moore, Ad Lightning; Ambika Singh, Armoire; Milkana Brace, Jargon; and Forest Key, Pixvana. (Photos courtesy Athira; Ad Lightning; Timoth... |
| - | Athira Pharma raises $85 million in Series B round | Below are some of the biopharma and health technology startups that have raised funding this week.
Athira Pharma
Headquarters: Seattle
Funding type: Series B
Amount raise: $85 million
Athira Pharma said Thursday that it had raised $85 milli... |
| - | Ex-Athira Pharma CEO Leen Kawas Starts $150M Fund With Key Investors From Former Company | Leen Kawas, the Seattle biotech exec who resigned as CEO of Athira Pharma after an investigation found she had altered doctoral research images that helped to form the initial basis for the company, re-emerged Friday as co-founder and manag... |
